Replimune Group, Inc. (REPL)
4.675
+0.08
(+1.63%)
USD |
NASDAQ |
May 27, 15:45
Replimune Group Cash from Investing (Quarterly) : 75.12M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| REGENXBIO, Inc. | 70.59M |
| Catalyst Pharmaceuticals, Inc. | -0.027M |
| Spyre Therapeutics, Inc. | 56.58M |
| Bristol Myers Squibb Co. | -131.00M |
| ANI Pharmaceuticals, Inc. | -11.32M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.96M |
| Cash from Financing (Quarterly) | 10.45M |
| Free Cash Flow | -283.27M |
| Free Cash Flow Per Share (Quarterly) | -0.7169 |
| Free Cash Flow to Equity (Quarterly) | -66.11M |
| Free Cash Flow to Firm (Quarterly) | -64.13M |
| Free Cash Flow Yield | -68.72% |